The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial...
Hence then, the article about menarini group reports data from the phase 3 sentry trial of selinexor plus ruxolitinib in myelofibrosis at the european hematology association eha 2026 congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress )
Also on site :
- James Denton Returns to Hallmark in Tearjerker Holiday Movie ‘A Season of Promises’ — Get a Sneak Peek
- The midterms didn’t stop the AI buildout. They simply repriced it—and OpenAI is already promising to pay up
- Tom Hanks called this 95% Rotten Tomatoes show ‘one of the greatest things’ he’s ever watched (hint: It’s not ‘Breaking Bad,’ ‘GOT’ or ‘The Sopranos)